Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Pavel Klener, prof.MD,PhD
CONTACT
Marketa Petrova, Ing.
CONTACT
Lead
Czech Lymphoma Study Group
Primary objective: Efficacy: to evaluate the efficacy of the combination of polatuzumab vedotin plus bendamustine and rituximab (BR) with respect to progression-free survival (PFS) Secondary objectives: Efficacy: to evaluate the efficacy of polatuzumab vedotin plus BR with respect to secondary efficacy endpoints, namely overall response rate, duration of response, event free survival and overall survival; Safety objective; Exploratory objectives
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted